PMID- 19588527
OWN - NLM
STAT- MEDLINE
DCOM- 20100120
LR  - 20211020
IS  - 1554-527X (Electronic)
IS  - 0736-0266 (Print)
IS  - 0736-0266 (Linking)
VI  - 28
IP  - 1
DP  - 2010 Jan
TI  - Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open 
      fractures.
PG  - 48-54
LID - 10.1002/jor.20939 [doi]
AB  - The increasing incidence of bacterial infection and the appearance of 
      Staphylococcus aureus (S. aureus) strains that are resistant to commonly used 
      antibiotics has made it important to develop non-antibiotic approaches for 
      infection prevention. The aim of this study was to develop local monocyte 
      chemoattractant protein-1 (MCP-1) and interleukin-12 p70 (IL-12 p70) therapies to 
      prevent S. aureus infection by enhancing the recruitment and activation of 
      macrophages, which are believed to play an important role in infection prevention 
      as the first line of defense against invading pathogens. Nanocoating systems for 
      MCP-1 and IL-12 p70 deliveries were prepared, and their release characteristics 
      desirable for infection prevention in open fractures were explored. Local MCP-1 
      therapy reduced S. aureus infection and influenced white blood cell populations, 
      and local IL-12 p70 treatment had a more profound effect on preventing S. aureus 
      infection. No synergistic relationship in decreasing S. aureus infection was 
      observed when MCP-1 and IL-12 p70 treatments were combined. This reported new 
      approach may reduce antibiotic use and antibiotic resistance.
FAU - Li, Bingyun
AU  - Li B
AD  - Biomaterials, Bioengineering & Nanotechnology Laboratory, Department of 
      Orthopaedics, School of Medicine, West Virginia University, Morgantown, West 
      Virginia 26506, USA. bli@hsc.wvu.edu
FAU - Jiang, Bingbing
AU  - Jiang B
FAU - Dietz, Matthew J
AU  - Dietz MJ
FAU - Smith, E Suzanne
AU  - Smith ES
FAU - Clovis, Nina B
AU  - Clovis NB
FAU - Rao, K Murali Krishna
AU  - Rao KM
LA  - eng
GR  - P20 RR016440/RR/NCRR NIH HHS/United States
GR  - RR16440/RR/NCRR NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Orthop Res
JT  - Journal of orthopaedic research : official publication of the Orthopaedic 
      Research Society
JID - 8404726
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Peptide Fragments)
RN  - 0 (monocyte chemoattractant protein 1 (66-77))
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/pharmacokinetics
MH  - Animals
MH  - Bone Wires/adverse effects
MH  - Chemokine CCL2/*administration & dosage/pharmacokinetics
MH  - Coated Materials, Biocompatible/*administration & dosage/pharmacokinetics
MH  - Disease Models, Animal
MH  - Drug Resistance, Bacterial
MH  - Femoral Fractures/complications/surgery
MH  - Fracture Fixation, Intramedullary/adverse effects/instrumentation
MH  - Fractures, Open/complications/*surgery
MH  - Interleukin-12/administration & dosage/pharmacokinetics
MH  - Internal Fixators/adverse effects
MH  - Male
MH  - *Nanostructures
MH  - Nanotechnology/methods
MH  - Osteomyelitis/microbiology/*prevention & control
MH  - Peptide Fragments/*administration & dosage/pharmacokinetics
MH  - Prosthesis Design
MH  - Prosthesis-Related Infections/microbiology/*prevention & control
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Staphylococcal Infections/microbiology/*prevention & control
MH  - Staphylococcus aureus/drug effects
PMC - PMC3886371
MID - NIHMS186356
EDAT- 2009/07/10 09:00
MHDA- 2010/01/21 06:00
PMCR- 2014/01/09
CRDT- 2009/07/10 09:00
PHST- 2009/07/10 09:00 [entrez]
PHST- 2009/07/10 09:00 [pubmed]
PHST- 2010/01/21 06:00 [medline]
PHST- 2014/01/09 00:00 [pmc-release]
AID - 10.1002/jor.20939 [doi]
PST - ppublish
SO  - J Orthop Res. 2010 Jan;28(1):48-54. doi: 10.1002/jor.20939.